



New Insights on Antibiotic Therapy in Chronic Lung Diseases

Guest Editor:

Prof. Dr. Riccardo Inchingolo

UOC Pneumologia, Fondazione
Policlinico Universitario A.
Gemelli IRCCS, Rome, Italy

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Dear Colleagues,

Chronic non-communicable respiratory diseases are among the top ten causes of death and disability in the world. In particular, chronic obstructive pulmonary disease affects nearly 4% of the world's population, making it the third leading cause of death in the world. Antibiotic use can influence the prognosis and acute exacerbation of chronic respiratory diseases, including treatment failure and hospitalization. Antimicrobial resistance is one of the top ten global threats to public health. The difficulty in developing new antibiotic drugs is well known, with the approval of only five new classes of antibiotics that target Gram-positive bacteria in the past 20 years and fewer than 50 new antibiotics currently under clinical development. The result is a global call for therapeutic strategies based on "traditional" and "non-traditional" antibiotics, including vaccines, antibodies, phage therapies, lysines, virulence-targeting agents, synthetic peptides and immunomodulators. With this global approach in mind, this Special Issue seeks proposals that focus on new developments of antibiotic therapy in patients with chronic lung diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi